Brain tumor and Gliadel wafer treatment

Indian Journal of Cancer

Volumn 48, Issue 1, 2011, Pages 11-17

  Panigrahi, M ^a   Das, P K ^b   Parikh, P M ^c  

^a KRISHNA INSTITUTE OF MEDICAL SCIENCES   (India)

^b INDRAPRASTHA APOLLO HOSPITAL   (India)

^c Indian Co operative Oncology Network   (India)

Author keywords

1,3 bis (2 chloroethyl) 1 nitrosourea or carmustine; Biological therapy; brain tumor; chemotherapy; Gliadel wafer; glioblastoma; gliomas; polifeprosan 20

Indexed keywords

5 AMINO 1 [3,5 DICHLORO 4 (4 CHLOROBENZOYL)BENZYL] 1H 1,2,3 TRIAZOLE 4 CARBOXAMIDE; BEVACIZUMAB; CANCER VACCINE; CARMUSTINE; CISPLATIN; IRINOTECAN; LOMUSTINE; PROCARBAZINE; TEMOZOLOMIDE; THALIDOMIDE;

ADVERSE OUTCOME; ASTROCYTE; BLOOD BRAIN BARRIER; CANCER CHEMOTHERAPY; CANCER GENE THERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER SURGERY; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; DRUG DELIVERY SYSTEM; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GENE DELIVERY SYSTEM; GLIADEL WAFER; GLIOBLASTOMA; HUMAN; IMMUNOTHERAPY; MOLECULARLY TARGETED THERAPY; PROGNOSIS;

ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CARMUSTINE; DELAYED-ACTION PREPARATIONS; HUMANS;

EID: 79951990891     PISSN: 0019509X     EISSN: 19984774     Source Type: Journal    
DOI: 10.4103/0019-509X.76623     Document Type: Conference Paper

References (19)

1. Avgeropoulos NG, Batchelor TT. New treatment strategies for malignant gliomas. Oncologist 1999;4:209-24. (Pubitemid 29297484)
2. National Cancer Institute. U.S. National Institutes of Health. Available from: http://www.cancer.gov. [cited in 2010].
3. American Brian Tumor Association. Available from: http://www.abta.org. [cited in 2010].
4. Aoki T, Hashimoto N, Matsutani M. Management of glioblastoma. Exp Opin Pharmacother 2007;8:3133-46.
5. Brandes AA, Tosoni A, Spagnolli F, Frezza G, Leonardi M, Calbucci F, et al. Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: Pitfalls in neurooncology. Neuro Oncol 2008;10:361-7.
6. Elkharraz K, Faisant N, Guse C, Siepmann F, Arica-Yegin B, Oger JM, et al. Paclitaxel-loaded microparticles and implants for the treatment of brain cancer: Preparation and physicochemical characterization. International Journal of Pharmaceutics 2006;314:127-36.
7. Raghavan R, Brady ML, Rodríguez-Ponce MI, Hartlep A, Pedain C, Sampson JH. Convection-enhanced delivery of therapeutics for brain disease, and its optimization. Neurosurg Focus 2006;20:E12.
8. Mamelak AN, Jacoby DB. Targeted delivery of antitumoral therapy to glioma and other malignancies with synthetic chlorotoxin (TM-601). Expert Opin Drug Deliv 2007;4:175-86. (Pubitemid 46389915)
9. Mamelak AN, Rosenfeld S, Bucholz R, Raubitschek A, Nabors LB, Fiveash JB, et al. Phase I single-dose study of intracavitary-administered iodine-131-TM-601 in adults with recurrent high-grade glioma. J Clin Oncol 2006;24:3644-50. (Pubitemid 46630539)
10. Schneider T, Becker A, Ringe K, Reinhold A, Firsching R, Sabel BA. Brain tumor therapy by combined vaccination and antisense oligonucleotide delivery with nanoparticles. J Neuroimmunol 2008;195:21-7.
11. Pastan I, Hassan R, Fitzgerald DJ, Kreitman RJ. Opinion: Immunotoxin therapy of cancer. Nat Rev Cancer 2006;6:559-65.
12. Tannous BA, Christensen AP, Pike L, Wurdinger T, Perry KF, Saydam O, et al. Mutant sodium channel for tumor therapy. Mol Ther 2009;17:810-9.
13. Lin SH, Kleinberg LR. Carmustine wafers: Localized delivery of chemotherapeutic agents in CNS malignancies. Expert Rev Anticancer Ther 2008;8:343-59. (Pubitemid 351836283)
14. Affronti ML, Heery CR, Herndon JE 2nd, Rich JN, Reardon DA, Desjardins A, et al. Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy. Cancer 2009;115:3501-11.
15. Fleming AB, Saltzman WM. Pharmacokinetics of the carmustine implant. Clin Pharmacokinet 2002;41:403-19. (Pubitemid 34753678)
16. Westphal M, Ram Z, Riddle V, Hilt D, Bortey E; Executive Committee of the Gliadel Study Group. Gliadel wafer in initial surgery for malignant glioma: Long-term follow-up of a multicenter controlled trial. Acta Neurochir (Wien) 2006;148:269-75
17. McGirt MJ, Than KD, Weingart JD, Chaichana KL, Attenello FJ, Olivi A, et al. Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme. J Neurosurg 2009;110:583-8.
18. Attenello FJ, Mukherjee D, Datoo G, McGirt MJ, Bohan E, Weingart JD, et al. Use of Gliadel (BCNU) wafer in the surgical treatment of malignant glioma: A 10-year institutional experience. Ann Surg Oncol 2008;15:2887-93.
19. Weber EL, Goebel EA. Cerebral edema associated with Gliadel wafers: Two case studies. Neuro Oncol 2005;7:84-9. (Pubitemid 40310196)